How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models' projections for England.

BMJ Open
Gwyn BevanRosalind Raine

Abstract

To examine validity of prevalence-based models giving projections of prevalence of diabetes in adults, in England and the UK, and of Markov chain models giving estimates of economic impacts of interventions to prevent type 2 diabetes (T2D). Rapid reviews of both types of models. Estimation of the future prevalence of T2D in England by Markov chain models; and from the trend in the prevalence of diabetes, as reported in the Quality and Outcomes Framework (QOF), estimated by ordinary least squares regression analysis. Adult population in England and UK. Prevalence of T2D in England and UK in 2025. The prevalence-based models reviewed use sample estimates of past prevalence rates by age and sex and projected population changes. Three most recent models, including that of Public Health England (PHE), neither take account of increases in obesity, nor report Confidence Intervals (CIs). The Markov chain models reviewed use transition probabilities between states of risk and death, estimated from various sources. None of their accounts give the full matrix of transition probabilities, and only a minority report tests of validation. Their primary focus is on estimating the ratio of costs to benefits of preventive interventions in those ...Continue Reading

References

Jul 1, 1992·Diabetes Care·M I HarrisM W Knuiman
Sep 1, 1991·American Journal of Public Health·S E MossB E Klein
Sep 28, 1996·BMJ : British Medical Journal·P RossingH H Parving
May 10, 2001·JAMA : the Journal of the American Medical Association·F de VegtR J Heine
May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
May 22, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN CDC Diabetes Cost-effectiveness Group
Jun 28, 2002·Lancet·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trail Research Group
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Mar 1, 2003·Diabetes Care·UNKNOWN DECODE Study Group, European Diabetes Epidemiology Group
Oct 23, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·J J CaroJ A O'Brien
Mar 2, 2005·Annals of Internal Medicine·William H HermanUNKNOWN Diabetes Prevention Program Research Group
Apr 20, 2005·Annals of Internal Medicine·Trevor J OrchardUNKNOWN Diabetes Prevention Program Research Group
Jul 21, 2005·Das Gesundheitswesen·A IcksUNKNOWN KORA Study Group
Nov 25, 2005·Diabetes Care·Honghong ZhouWilliam H Herman
Apr 23, 2008·BMJ : British Medical Journal·Clare L GilliesKamlesh Khunti
Jul 10, 2009·Diabetes Care·Leigh PerreaultUNKNOWN Diabetes Prevention Program Research Group
Jul 22, 2009·International Journal of Technology Assessment in Health Care·Pia JohanssonPer Tillgren
Nov 10, 2009·Diabetes Research and Clinical Practice·J E ShawP Z Zimmet
Mar 5, 2010·The New England Journal of Medicine·Elizabeth SelvinFrederick L Brancati
Apr 23, 2010·Applied Health Economics and Health Policy·Thilo M Schaufler, Malte Wolff
Apr 13, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·N HolmanS H Wild
Nov 15, 2011·Diabetes Research and Clinical Practice·David R WhitingJonathan Shaw
Mar 20, 2012·American Journal of Preventive Medicine·Xiaohui ZhuoEdward W Gregg

❮ Previous
Next ❯

Software Mentioned

R
Excel

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.